Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies
Pfizer to Present Cancer Therapies at ASCO Annual Meeting, Including Advances in ADCs and Bispecific Antibodies
辉瑞将在ASCO年会上介绍癌症疗法，包括ADC和双特异性抗体的进展
Pfizer Inc. (NYSE:PFE) highlights its progress in advancing new potential standards of care in Oncology at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, taking place May 31 to June 4 in Chicago. More than 50abstracts, including 11oral presentations, will be presented from Pfizer's broadened portfolio of approved and pipeline therapies across the company's key tumor areas and core scientific modalities, including small molecules, antibody-drug conjugates (ADCs) and bispecific antibodies.
辉瑞公司（纽约证券交易所代码：PFE）在5月31日至6月4日在芝加哥举行的2024年美国临床肿瘤学会（ASCO）年会上重点介绍了其在推进新的潜在肿瘤学护理标准方面取得的进展。辉瑞在公司关键肿瘤领域和核心科学模式（包括小分子、抗体药物偶联物（ADC）和双特异性抗体）中扩大了已获批准和在研的疗法产品组合，将发表50多份摘要，包括11份口头演讲。
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。